Total Payments
$4,199
2024 Payments
$949.30
Companies
50
Transactions
244
Medicare Patients
20,737
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$4,031 (96.0%)
Education$167.53 (4.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,031 | 237 | 96.0% |
| Education | $167.53 | 7 | 4.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $475.32 | 26 | $0 (2024) |
| PFIZER INC. | $419.65 | 29 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $373.72 | 21 | $0 (2024) |
| Exelixis Inc. | $285.61 | 7 | $0 (2022) |
| Merck Sharp & Dohme LLC | $235.91 | 16 | $0 (2024) |
| Genentech USA, Inc. | $232.08 | 13 | $0 (2021) |
| Janssen Biotech, Inc. | $222.02 | 15 | $0 (2024) |
| BeiGene USA, Inc. | $135.53 | 8 | $0 (2024) |
| Deciphera Pharmaceuticals Inc. | $114.02 | 7 | $0 (2024) |
| Eisai Inc. | $107.79 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $949.30 | 50 | Celgene Corporation ($162.93) |
| 2023 | $754.26 | 46 | Celgene Corporation ($138.84) |
| 2022 | $680.95 | 40 | Novartis Pharmaceuticals Corporation ($95.21) |
| 2021 | $452.02 | 27 | EISAI INC. ($93.88) |
| 2020 | $91.10 | 6 | PFIZER INC. ($20.56) |
| 2019 | $687.38 | 34 | Exelixis Inc. ($180.16) |
| 2018 | $316.98 | 22 | Merck Sharp & Dohme Corporation ($65.23) |
| 2017 | $266.85 | 19 | PFIZER INC. ($46.26) |
All Payment Transactions
244 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: Oncology | ||||||
| 11/18/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $10.55 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/14/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug), TGCT | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | PFIZER INC. | INLYTA (Drug), IBRANCE, TUKYSA | Food and Beverage | In-kind items and services | $4.10 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $30.09 | General |
| Category: Hematology | ||||||
| 10/24/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $15.01 | General |
| Category: Hematology | ||||||
| 10/14/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $33.40 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.26 | General |
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | Myriad Genetic Laboratories, Inc. | BRACANALYSIS CDX (Device) | Food and Beverage | In-kind items and services | $59.30 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/06/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.65 | General |
| 09/04/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $19.00 | General |
| 09/03/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $18.64 | General |
| Category: Hematology | ||||||
| 08/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.98 | General |
| 08/14/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 505 | 687 | $170,036 | $57,826 |
| 2022 | 4 | 570 | 830 | $200,941 | $69,709 |
| 2021 | 42 | 9,781 | 23,797 | $1.1M | $509,693 |
| 2020 | 43 | 9,881 | 24,445 | $1.1M | $455,959 |
Total Patients
20,737
Total Services
49,759
Medicare Billing
$1.1M
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 271 | 385 | $79,435 | $24,769 | 31.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 160 | 228 | $63,178 | $23,964 | 37.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 57 | 57 | $22,136 | $7,463 | 33.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $5,287 | $1,630 | 30.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 330 | 513 | $106,553 | $35,344 | 33.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 169 | 246 | $68,396 | $25,475 | 37.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 48 | 48 | $18,893 | $6,728 | 35.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $7,099 | $2,162 | 30.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 869 | 2,123 | $437,338 | $196,509 | 44.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 283 | 611 | $168,636 | $81,742 | 48.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 988 | 2,871 | $68,904 | $30,245 | 43.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 1,061 | 3,406 | $61,308 | $26,398 | 43.1% |
| 82728 | Ferritin (blood protein) level | Office | 2021 | 715 | 1,761 | $54,591 | $23,894 | 43.8% |
| 84466 | Transferrin (iron binding protein) level | Office | 2021 | 712 | 1,751 | $50,779 | $22,244 | 43.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 88 | 88 | $34,408 | $14,084 | 40.9% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2021 | 274 | 574 | $26,978 | $11,945 | 44.3% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2021 | 823 | 1,942 | $27,188 | $11,700 | 43.0% |
| 83540 | Iron level | Office | 2021 | 712 | 1,755 | $26,325 | $11,322 | 43.0% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2021 | 340 | 692 | $23,528 | $10,395 | 44.2% |
| 82746 | Folic acid level, serum | Office | 2021 | 335 | 678 | $22,374 | $9,927 | 44.4% |
| 82306 | Vitamin d-3 level | Office | 2021 | 212 | 259 | $17,094 | $7,647 | 44.7% |
| 85045 | Red blood count, automated test | Office | 2021 | 794 | 1,895 | $17,055 | $7,541 | 44.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 73 | 75 | $10,500 | $4,886 | 46.5% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2021 | 86 | 507 | $10,647 | $4,715 | 44.3% |
| 86320 | Immunologic analysis technique on serum | Office | 2021 | 81 | 150 | $9,000 | $4,466 | 49.6% |
About Dr. Stephen Davidson, MD
Dr. Stephen Davidson, MD is a Medical Oncology healthcare provider based in Montgomery, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902852171.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Davidson, MD has received a total of $4,199 in payments from pharmaceutical and medical device companies, with $949.30 received in 2024. These payments were reported across 244 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($4,031).
As a Medicare-enrolled provider, Davidson has provided services to 20,737 Medicare beneficiaries, totaling 49,759 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Montgomery, AL
- Active Since 05/26/2006
- Last Updated 07/19/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1902852171
Products in Payments
- REBLOZYL (Biological) $316.52
- Cabometyx (Drug) $285.61
- KEYTRUDA (Biological) $235.91
- IMBRUVICA (Drug) $148.15
- BRUKINSA (Drug) $117.94
- IBRANCE (Drug) $114.63
- QINLOCK (Drug) $114.02
- Lenvima (Drug) $107.79
- GAZYVA (Biological) $101.51
- Rituxan (Biological) $99.95
- Pomalyst (Drug) $99.39
- OPDIVO (Biological) $93.17
- PROMACTA (Drug) $85.66
- LIBTAYO (Biological) $82.25
- BOSULIF (Drug) $78.86
- MEKINIST (Drug) $72.59
- MONJUVI (Drug) $69.58
- XALKORI (Drug) $67.74
- PLUVICTO (Drug) $61.83
- BRACANALYSIS CDX (Device) $59.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.